Pathologic node involvement as a prognostic factor in HER2-amplified primary breast cancer (BC) patients (pts) treated without trastuzumab
| Autor: | Thomas Bachelot, Olivier Tredan, D. Perol, T. Gargi, Sylvie Chabaud, Isabelle Treilleux, V. Bourdes |
|---|---|
| Rok vydání: | 2008 |
| Předmět: |
Gynecology
Oncology Cancer Research medicine.medical_specialty Chemotherapy Univariate analysis business.industry Proportional hazards model Lymphovascular invasion medicine.medical_treatment medicine.anatomical_structure Trastuzumab Internal medicine Cohort medicine Stage (cooking) skin and connective tissue diseases business Lymph node medicine.drug |
| Zdroj: | Journal of Clinical Oncology. 26:11537-11537 |
| ISSN: | 1527-7755 0732-183X |
| DOI: | 10.1200/jco.2008.26.15_suppl.11537 |
| Popis: | 11537 Background: Current management of BC pts with HER2 overexpression includes chemotherapy and trastuzumab treatment. In order to assess the potential individual benefit of this treatment we analyzed outcome data and prognostic factors in a prospectively characterized cohort of HER2 positive BC pts treated before the trastuzumab era. Methods: Medical records from 103 HER2 positive BC pts treated between 1996 and 2005 according to our standard institutional protocols without adjuvant trastuzumab were analyzed. Clinicopathologic variables such as age, menopausal status, clinical stage, pathologic tumor size (pTS), histologic grade (HG), ER and PR status, lymphovascular invasion (LVI) and axillary lymph node (ALN) status were extracted from the institutional database that has been prospectively collected since 1996. Variables with a 0.15 significance level in univariate analysis were entered in a multivariate Cox model. A backward stepwise procedure discriminated non-influential variables at 0.05 level. R... |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|